Drugs / FLIZASERTIB
FLIZASERTIB
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05673876 | Apr 2023 → Jan 2024 | acute graft versus host disease | Genentech, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06602453 | Jan 2025 → Mar 2026 | acute kidney injury | Genentech, Inc. | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FLIZASERTIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314462 ↗ |
| Known as | GDC-8264 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05673876 ↗ |
| Known as | RG-6287 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314462 ↗ |
| Known as | RO-7288817 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314462 ↗ |
| Modality | Small molecule | — CHEMBL5314462 ↗ |
| Route | Oral | “Participants will receive oral GDC-8264” NCT05673876 ↗ |